Sanofi (NASDAQ:SNY) said on Tuesday that the US FDA has granted priority review to the regulatory submission of tolebrutinib ...

This Phase 2 trial aims to assess the safety, tolerability, and foralumab’s effect on microglial activation in patients with na-SPMS. Intranasal foralumab offers a novel approach to potentially ...

A significant benefit was observed with Tysabri over Rebif in delaying SPMS disability progression when therapeutic lag was ...

Fortunately, the S&P 500 recovered to new all-time highs by August 2020 and is now up about 150% from its COVID lows.

Observational studies and two randomized controlled trials consistently suggest that, in general, disease recurrence after ...

In the first major deal at MIT’s ambitious overhaul of the old Volpe Center in Kendall Square, Cambridge drugmaker Biogen ...

Studies have shown that starting a high-efficacy DMT like Tysabri earlier in the disease course can also lead to less ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

The link between neuroinflammation and the progression of multiple sclerosis (MS) is unclear. Here, the authors show that in MS lesions, neuronal somatic mutations accumulate 2.5 times faster than ...

Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?

High-dose vitamin D supplementation reduces disease activity in clinically isolated syndrome typical of MS, results of a ...

There are 4 main types of multiple sclerosis (MS), which differ based on how the disease has progressed. The treatment options and long-term outlook can depend on your MS type. Multiple sclerosis ...